Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 301

1.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

2.

A single cycle of rituximab for the treatment of severe pemphigus.

Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P.

N Engl J Med. 2007 Aug 9;357(6):545-52.

3.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
4.

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.

Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D.

Br J Dermatol. 2008 Feb;158(2):382-8. Epub 2007 Dec 6.

PMID:
18070210
5.

Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.

Feldman RJ, Christen WG, Ahmed AR.

Br J Dermatol. 2012 Mar;166(3):511-7. doi: 10.1111/j.1365-2133.2011.10658.x. Epub 2012 Jan 19.

PMID:
21967407
6.

Rituximab in refractory pemphigus vulgaris.

Sorce M, Aricò M, Bongiorno MR.

Dermatol Ther. 2008 Jul;21 Suppl 1:S6-9. doi: 10.1111/j.1529-8019.2008.00194.x.

PMID:
18727815
7.

Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.

Faurschou A, Gniadecki R.

Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365-4632.2008.03423.x.

PMID:
18289336
8.

Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.

Rheumatology (Oxford). 2006 Nov;45(11):1432-6. Epub 2006 Apr 21.

PMID:
16632482
9.

Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.

El Tal AK, Posner MR, Spigelman Z, Ahmed AR.

J Am Acad Dermatol. 2006 Sep;55(3):449-59. Review.

PMID:
16908351
10.

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

Dupuy A, Viguier M, Bédane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H.

Arch Dermatol. 2004 Jan;140(1):91-6.

PMID:
14732665
11.

Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.

Matsukura S, Knowles SR, Walsh S, Shear NH.

Arch Dermatol. 2012 Jun;148(6):734-9. doi: 10.1001/archdermatol.2011.3320. Erratum in: Arch Dermatol. 2012 Sep 1;148(9):1012. Dosage error in article text. Arch Dermatol. 2012 Aug;148(8):970. Dosage error in article text.

PMID:
22351790
12.

[Treatment of severe refractory pemphigus vulgaris with rituximab].

Pitarch G, Sánchez-Carazo JL, Pardo J, Torrijos A, Roche E, Fortea JM.

Actas Dermosifiliogr. 2006 Jan-Feb;97(1):48-51. Review. Spanish.

PMID:
16540052
13.

Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease.

Khosroshahi A, Bloch DB, Deshpande V, Stone JH.

Arthritis Rheum. 2010 Jun;62(6):1755-62. doi: 10.1002/art.27435.

14.

Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.

Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P.

Arch Dermatol. 2007 Aug;143(8):1033-8. Review.

PMID:
17709662
15.

Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.

Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM.

Br J Dermatol. 2007 May;156(5):990-6. Epub 2007 Mar 13.

PMID:
17355229
16.

Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.

Arin MJ, Engert A, Krieg T, Hunzelmann N.

Br J Dermatol. 2005 Sep;153(3):620-5.

PMID:
16120153
17.

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

Kong HH, Prose NS, Ware RE, Hall RP 3rd.

Pediatr Dermatol. 2005 Sep-Oct;22(5):461-4.

PMID:
16191003
18.

Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.

Barrera MV, Mendiola MV, Bosch RJ, Herrera E.

J Dermatolog Treat. 2007;18(5):312-4.

PMID:
17852643
19.

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.

Sami N, Qureshi A, Ruocco E, Ahmed AR.

Arch Dermatol. 2002 Sep;138(9):1158-62.

PMID:
12224976
20.

Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.

Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U, Blaszczyk M.

Am J Clin Dermatol. 2007;8(2):85-92.

PMID:
17428113

Supplemental Content

Support Center